D-Wave Quantum (QBTS) and the pharmaceutical division of Japan Tobacco said Monday that they completed a joint proof-of-concept project adapting D-Wave's quantum computing technology and artificial intelligence for the drug discovery process.
The companies developed hybrid large language models that generated "more valid" molecules with a higher quantitative estimate of drug-likeness, compared with classical methods alone, they said.
Following the proof-of-concept project, Japan Tobacco's pharmaceutical division now plans to further advance development of quantum AI-driven drug discovery technology for molecular design, the companies said.
Price: 7.59, Change: +0.01, Percent Change: +0.15
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。